<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=2383&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="522018" class="table-">
                
                <td>May 16, 2025, 8 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Geometric Mean Fold Rise (GMFR) in SARS-CoV-2 Neutralizing Antibody Titers Post Booster Vaccination;Geometric Mean Fold Rise (GMFR) in SARS-CoV-2 Neutralizing Antibody Titers Post Priming Vaccination;Geometric Mean Titer (GMT) of Serum Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibodies Post Priming Vaccination;GMFR in SARS-CoV-2 Neutralizing Antibody Titers Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Priming Vaccination;Percentage of Participants Reporting Solicited Local Adverse Events Within 7 Days Post Booster Vaccination;Percentage of Participants Reporting Solicited Local Adverse Events Within 7 Days Post Each Priming Vaccination;Percentage of Participants Reporting Solicited Systemic Adverse Events Within 7 Days Post Booster Vaccination;Percentage of Participants Reporting Solicited Systemic Adverse Events Within 7 Days Post Each Priming Vaccination;Percentage of Participants Reporting Treatment-emergent Serious Adverse Events, Medically Attended Adverse Events and New Onset of Chronic Disease Post Booster Vaccination;Percentage of Participants Reporting Treatment-Emergent Serious Adverse Events (SAE), Medically Attended Adverse Events (MAAE) and New Onset of Chronic Disease (NOCD) Post Each Priming Vaccination;Percentage of Participants Reporting Unsolicited Adverse Events Up to 28 Days Post Booster Vaccination;Percentage of Participants Reporting Unsolicited Adverse Events Up to 28 Days Post Each Priming Vaccination;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 208;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 236;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 56
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Geometric Mean Fold Rise (GMFR) in SARS-CoV-2 Neutralizing Antibody Titers Post Booster Vaccination;Geometric Mean Fold Rise (GMFR) in SARS-CoV-2 Neutralizing Antibody Titers Post Priming Vaccination;Geometric Mean Titer (GMT) of Serum Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibodies Post Priming Vaccination;GMFR in SARS-CoV-2 Neutralizing Antibody Titers Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Priming Vaccination;Percentage of Participants Reporting Solicited Local Adverse Events Within 7 Days Post Booster Vaccination;Percentage of Participants Reporting Solicited Local Adverse Events Within 7 Days Post Each Priming Vaccination;Percentage of Participants Reporting Solicited Systemic Adverse Events Within 7 Days Post Booster Vaccination;Percentage of Participants Reporting Solicited Systemic Adverse Events Within 7 Days Post Each Priming Vaccination;Percentage of Participants Reporting Treatment-emergent Serious Adverse Events, Medically Attended Adverse Events and New Onset of Chronic Disease Post Booster Vaccination;Percentage of Participants Reporting Treatment-Emergent Serious Adverse Events (SAE), Medically Attended Adverse Events (MAAE) and New Onset of Chronic Disease (NOCD) Post Each Priming Vaccination;Percentage of Participants Reporting Unsolicited Adverse Events Up to 28 Days Post Booster Vaccination;Percentage of Participants Reporting Unsolicited Adverse Events Up to 28 Days Post Each Priming Vaccination;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 208;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 236;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 56
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="77808" class="table-">
                
                <td>Dec. 18, 2020, 12:31 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs;Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels;Percentages of participants reporting adverse events;Percentages of participants reporting medically attended adverse events;Percentages of participants reporting new onset of chronic disease;Percentages of participants reporting serious adverse events;Percentages of participants reporting solicited local adverse events;Percentages of participants reporting solicited systemic adverse events;Percentages of participants with abnormal chemistry and hematology values;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs;Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels;Percentages of participants reporting adverse events;Percentages of participants reporting medically attended adverse events;Percentages of participants reporting new onset of chronic disease;Percentages of participants reporting serious adverse events;Percentages of participants reporting solicited local adverse events;Percentages of participants reporting solicited systemic adverse events;Percentages of participants with abnormal chemistry and hematology values;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
May 16, 2025, 8 a.m.	usa	Geometric Mean Fold Rise (GMFR) in SARS-CoV-2 Neutralizing Antibody Titers Post Booster Vaccination;Geometric Mean Fold Rise (GMFR) in SARS-CoV-2 Neutralizing Antibody Titers Post Priming Vaccination;Geometric Mean Titer (GMT) of Serum Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibodies Post Priming Vaccination;GMFR in SARS-CoV-2 Neutralizing Antibody Titers Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Priming Vaccination;Percentage of Participants Reporting Solicited Local Adverse Events Within 7 Days Post Booster Vaccination;Percentage of Participants Reporting Solicited Local Adverse Events Within 7 Days Post Each Priming Vaccination;Percentage of Participants Reporting Solicited Systemic Adverse Events Within 7 Days Post Booster Vaccination;Percentage of Participants Reporting Solicited Systemic Adverse Events Within 7 Days Post Each Priming Vaccination;Percentage of Participants Reporting Treatment-emergent Serious Adverse Events, Medically Attended Adverse Events and New Onset of Chronic Disease Post Booster Vaccination;Percentage of Participants Reporting Treatment-Emergent Serious Adverse Events (SAE), Medically Attended Adverse Events (MAAE) and New Onset of Chronic Disease (NOCD) Post Each Priming Vaccination;Percentage of Participants Reporting Unsolicited Adverse Events Up to 28 Days Post Booster Vaccination;Percentage of Participants Reporting Unsolicited Adverse Events Up to 28 Days Post Each Priming Vaccination;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 208;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 236;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 56	Geometric Mean Fold Rise (GMFR) in SARS-CoV-2 Neutralizing Antibody Titers Post Booster Vaccination;Geometric Mean Fold Rise (GMFR) in SARS-CoV-2 Neutralizing Antibody Titers Post Priming Vaccination;Geometric Mean Titer (GMT) of Serum Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibodies Post Priming Vaccination;GMFR in SARS-CoV-2 Neutralizing Antibody Titers Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Booster Vaccination;GMT of SARS-CoV-2 Neutralizing Antibodies Post Priming Vaccination;Percentage of Participants Reporting Solicited Local Adverse Events Within 7 Days Post Booster Vaccination;Percentage of Participants Reporting Solicited Local Adverse Events Within 7 Days Post Each Priming Vaccination;Percentage of Participants Reporting Solicited Systemic Adverse Events Within 7 Days Post Booster Vaccination;Percentage of Participants Reporting Solicited Systemic Adverse Events Within 7 Days Post Each Priming Vaccination;Percentage of Participants Reporting Treatment-emergent Serious Adverse Events, Medically Attended Adverse Events and New Onset of Chronic Disease Post Booster Vaccination;Percentage of Participants Reporting Treatment-Emergent Serious Adverse Events (SAE), Medically Attended Adverse Events (MAAE) and New Onset of Chronic Disease (NOCD) Post Each Priming Vaccination;Percentage of Participants Reporting Unsolicited Adverse Events Up to 28 Days Post Booster Vaccination;Percentage of Participants Reporting Unsolicited Adverse Events Up to 28 Days Post Each Priming Vaccination;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 208;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 236;Percentages of Participants Achieving Greater Than or Equal to 2-fold and 4-fold Increase From Before Vaccination (Baseline) in SARS-CoV-2 Serum Neutralizing Antibody Levels at Day 56
Dec. 18, 2020, 12:31 a.m.	usa	Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs;Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels;Percentages of participants reporting adverse events;Percentages of participants reporting medically attended adverse events;Percentages of participants reporting new onset of chronic disease;Percentages of participants reporting serious adverse events;Percentages of participants reporting solicited local adverse events;Percentages of participants reporting solicited systemic adverse events;Percentages of participants with abnormal chemistry and hematology values;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs	Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs;Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels;Percentages of participants reporting adverse events;Percentages of participants reporting medically attended adverse events;Percentages of participants reporting new onset of chronic disease;Percentages of participants reporting serious adverse events;Percentages of participants reporting solicited local adverse events;Percentages of participants reporting solicited systemic adverse events;Percentages of participants with abnormal chemistry and hematology values;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs